HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SKYE
Skye Bioscience, Inc.
There isn't enough reported data to score SKYE yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SKYE Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
SKYE's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SKYE PE Valuation
SKYE has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SKYE Forward outlook
There aren't enough analyst estimates for SKYE to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
SKYE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$10.24 | -$1.68 |
| Q1 2026 | -$11.60 | -$4.96 |
| Q4 2025 | -$11.28 | -$5.44 |
| Q3 2025 | -$10.32 | -$1.99 |
| Q2 2025 | -$8.56 | +$24.33 |
| Q1 2025 | -$6.64 | +$24.65 |
| Q4 2024 | -$5.84 | +$44.01 |
| Q3 2024 | -$8.33 | +$57.03 |
SKYE is still losing money, but far less than before: $10.24 per share over the past year, against $200.00 at its worst in late 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
SKYE Quarterly Revenue
SKYE and HIMS do not have enough comparable growth data to identify a winner.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SKYE on cash generation, producing positive trailing cash flow while its opponent burns cash.
SKYE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$7.1M | +$3.6M |
| Q1 2026 | -$8.6M | +$633.9K |
| Q4 2025 | -$9.8M | -$1.5M |
| Q3 2025 | -$13.4M | -$6.6M |
| Q2 2025 | -$10.7M | -$3.6M |
| Q1 2025 | -$9.2M | -$4.5M |
| Q4 2024 | -$8.2M | -$4.4M |
| Q3 2024 | -$6.8M | -$2.7M |
SKYE has burned cash in almost every quarter: −$39M over the past year, against −$35M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SKYE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SKYE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +1.6K shares |
| 1 year | +0.1% | +4.4K shares |
| 3 years | +921% | +4.5M shares |
| 5 years | +2846% | +4.8M shares |
| Available history | +7361% | +4.9M shares |
SKYE has 5M diluted shares, about the same as a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SKYE Net Leverage
SKYE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SKYE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.5 | Oversold |
| Stochastic | 3.2 | Oversold |
SKYE's weekly RSI is 24 (oversold) and its Stochastic is 3 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SKYE PE vs Healthcare Sector
| Metric | SKYE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SKYE has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SKYE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.44 | 25% below |
| 20 week MA | $2.77 | 61% below |
| 50 week MA | $5.07 | 79% below |
| 100 week MA | $13.2 | 92% below |
| 200 week MA | $30.3 | 96% below |
SKYE is in a downtrend: it's below all five of its weekly moving averages, and 96% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over SKYE on returns for 2026, with the stronger performance.
SKYE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $360.0 | $92.0 | -74% |
| 2021 | $92.0 | $106.0 | +15% |
| 2022 | $106.0 | $26.0 | -75% |
| 2023 | $26.0 | $21.8 | -16% |
| 2024 | $21.8 | $19.7 | -9.6% |
| 2025 | $19.7 | $6.40 | -67% |
| 2026 YTD | $6.40 | $1.08 | -83% |
SKYE has finished four years in a row lower, and it's down 83% so far in 2026.